Zydus Lifesciences (including its subsidiaries/affiliates hereafter referred to as ‘Zydus’) has received final approval from the United States Food and Drug Administration (USFDA) for Sirolimus Tablets, 1 mg and 2 mg (USRLD: Rapamune Tablets). Rapamune is used to prevent rejection (anti-rejection medicine) in people 13 years of age and older who have received a kidney transplant. It is also given to treat a rare lung disorder called lymphangioleiomyomatosis which predominantly affects women of childbearing age. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.
Sirolimus Tablets had annual sales of $69 million in the United States. The group now has 342 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.30 |
| Dr. Reddys Lab | 1238.30 |
| Cipla | 1236.40 |
| Zydus Lifesciences | 938.75 |
| Lupin | 2328.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: